The Role of Brentuximab Vedotin (BV) as Second-Line Treatment of Refractory Classical Hodgkin Lymphoma (cHL) in the Era of Pandemic COVID-19

BACKGROUND: Salvage conventional chemotherapy followed by high-dose therapy (HDT) and autologous stem cell transplantation (ASCT) is the treatment of choice for most patients with refractory classical Hodgkin lymphoma (cHL). In the era of pandemic COVID-19, there are obstacles to administering salva...

Descripción completa

Detalles Bibliográficos
Autores principales: Rajabto, Wulyo, Chandika, Vitya, Harahap, Agnes Stephanie, Ham, Maria Francisca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9167837/
https://www.ncbi.nlm.nih.gov/pubmed/35677855
http://dx.doi.org/10.2147/IMCRJ.S348718

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9167837/
https://www.ncbi.nlm.nih.gov/pubmed/35677855
http://dx.doi.org/10.2147/IMCRJ.S348718

Ejemplares similares